Amgen Inc (AMGN)vsDuke Energy Corporation (DUK)
AMGN
Amgen Inc
$338.02
+2.43%
HEALTHCARE · Cap: $182.22B
DUK
Duke Energy Corporation
$129.55
+2.40%
UTILITIES · Cap: $99.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Amgen Inc generates 16% more annual revenue ($36.75B vs $31.79B). AMGN leads profitability with a 21.0% profit margin vs 15.6%. AMGN appears more attractively valued with a PEG of 2.23. AMGN earns a higher WallStSmart Score of 70/100 (B-).
AMGN
Strong Buy70
out of 100
Grade: B-
DUK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-8.8%
Fair Value
$318.30
Current Price
$338.02
$19.72 premium
Margin of Safety
-64.7%
Fair Value
$78.65
Current Price
$129.55
$50.90 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 106 in profit
Strong operational efficiency at 30.5%
Earnings expanding 112.1% YoY
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 28.1%
Areas to Watch
Expensive relative to growth rate
Trading at 21.0x book value
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Earnings declined 2.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.
Bull Case : DUK
The strongest argument for DUK centers on Market Cap, Price/Book, Operating Margin. Profitability is solid with margins at 15.6% and operating margin at 28.1%.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book.
Bear Case : DUK
The primary concerns for DUK are Debt/Equity, Piotroski F-Score, PEG Ratio. Debt-to-equity of 1.75 is elevated, increasing financial risk.
Key Dynamics to Monitor
AMGN carries more volatility with a beta of 0.47 — expect wider price swings.
AMGN is growing revenue faster at 8.6% — sustainability is the question.
AMGN generates stronger free cash flow (961M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AMGN scores higher overall (70/100 vs 59/100), backed by strong 21.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Duke Energy Corporation
UTILITIES · UTILITIES - REGULATED ELECTRIC · USA
Duke Energy Corporation is an American electric power and natural gas holding company headquartered in Charlotte, North Carolina.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?